T. Rowe Price Associates
PRME icon

T. Rowe Price Associates’s Prime Medicine PRME Stock Holding History

T. Rowe Price Associates’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$466K Buy
133,755
+29,202
+28% +$111K ﹤0.01% 2495
2025
Q4 		$363K Buy
104,553
+30,051
+40% +$134K ﹤0.01% 2550
2025
Q3 		$413K Buy
74,502
+9,182
+14% +$37.3K ﹤0.01% 2446
2025
Q2 		$162K Sell
65,320
-1,501,872
-96% -$2.32M ﹤0.01% 2781
2025
Q1 		$3.12M Sell
1,567,192
-17,284
-1% -$44.1K ﹤0.01% 1410
2024
Q4 		$4.63M Buy
1,584,476
+38,515
+2% +$135K ﹤0.01% 1309
2024
Q3 		$5.98M Hold
1,545,961
– – ﹤0.01% 1244
2024
Q2 		$7.95M Sell
1,545,961
-976,629
-39% -$5.92M ﹤0.01% 1142
2024
Q1 		$17.7M Buy
2,522,590
+301,431
+14% +$2.29M ﹤0.01% 1004
2023
Q4 		$19.7M Buy
2,221,159
+47,788
+2% +$368K ﹤0.01% 961
2023
Q3 		$20.7M Sell
2,173,371
-160,460
-7% -$2.08M ﹤0.01% 913
2023
Q2 		$34.2M Buy
2,333,831
+1,430,090
+158% +$20M ﹤0.01% 814
2023
Q1 		$11.1M Sell
903,741
-1,474,841
-62% -$24M ﹤0.01% 1039
2022
Q4 		$44.2M Buy
+2,378,582
New +$43M 0.01% 696

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates's PRME Position: Q1 2026 in Review

T. Rowe Price Associates increased its Prime Medicine (PRME) stake by 28% in Q1 2026, buying an estimated $111K and bringing the position to 133,755 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

T. Rowe Price Associates first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $44.2M in Q4 2022. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • T. Rowe Price Associates held 133,755 shares of Prime Medicine worth $466K as of Q1 2026.
  • T. Rowe Price Associates bought 29,202 Prime Medicine shares in Q1 2026, an estimated $111K.
  • Prime Medicine made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2495 holding.
  • T. Rowe Price Associates first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Prime Medicine position peaked at $44.2M in Q4 2022.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.